바이오시뮬레이션 시장 : 제품별, 용도별, 전달 모델별, 최종사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

Biosimulation Market By Product, By Application, By Delivery model, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,917,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,264,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

바이오시뮬레이션 시장 2022년 시장 규모는 25억 달러로, 2032년에는 106억 달러에 달하며, 2023-2032년의 CAGR은 15.8%로 성장할 것으로 예측되고 있습니다.

인간의 생물학에 필수적인 생물학적 과정을 컴퓨터의 도움을 받아 시뮬레이션하는 것을 바이오시뮬레이션이라고 합니다. 바이오시뮬레이션의 목적은 모델을 기반으로 생체 시스템의 동역학과 거동을 예측하는 것입니다. 시뮬레이션 모델은 생물학적 시스템에 대한 지식을 수식으로 변환합니다. 의약품 개발 과정의 초기 단계에서는 첫 번째 분자가 생산되기 전에도 시뮬레이션 모델을 사용하여 모든 가설을 검증하고, 기능을 최적화하기 위해 제품을 변경하거나 특정 약물이 의약품으로 기능할 가능성을 추정할 수 있다고 가정합니다. 시뮬레이션 모델은 효과적인 시험 프로토콜을 정의하고 시험에서 얻은 정보의 일관성을 확인하는 수단으로 사용될 것으로 예상됩니다.

신약의 전임상시험, 후보물질 발굴 및 최적화, 표적의 식별 및 검증은 의약품 연구개발에서 바이오시뮬레이션이 활용되는 주요 분야입니다. 바이오시뮬레이션은 생물학, 화학, 약리학의 원리를 독자적인 알고리즘에 적용하여 의약품과 질병이 체내에서 어떻게 작용하는지를 정확하게 예측하는 것을 목표로 하는 '가상' 의약품 테스트의 근간을 이루고 있습니다. 또한 약물 상호 작용, 안전한 투여, 독성 예측 등에 대한 중요한 인사이트을 수집하는 것도 이 작업의 일환입니다.

세계 바이오시뮬레이션 시장의 성장을 가속하는 주요 요인으로는 신약 개발 및 시장 개척 수요 증가, 개인 맞춤형 의약품에 대한 수요 증가, 바이오시뮬레이션 소프트웨어 및 장비의 기술 발전이 급격하게 증가하고 있는 점을 들 수 있습니다. 예를 들어 바이오시뮬레이션 분야의 세계 리더인 Certara는 2022년 6월 면역원성(IG), 면역종양학(IO), 백신 시뮬레이터의 새로운 버전을 출시하여 약물의 작용을 예측하고 새로운 생물학적 치료법을 개발하는 데 중요한 질문을 해결하는 데 도움을 줄 수 있게 되었습니다.

또한 신약 개발을 위한 제약 및 생명공학 산업의 R&D 투자 증가와 암, 당뇨병, 알츠하이머, 심혈관 질환, 신장 질환과 같은 만성질환의 유병률 증가는 바이오시뮬레이션 소프트웨어에 대한 수요를 증가시키고 시장 성장을 가속하는 주요 요인으로 작용할 것으로 예상됩니다. 시장 성장을 가속하는 주요 요인이 되고 있습니다. 또한 신약 개발 및 R&D 비용 절감에 대한 수요 증가와 신약 개발 및 R&D를 위한 임상시험수탁기관(CRO) 및 학술연구기관에서 바이오시뮬레이션 소프트웨어의 보급률 증가는 바이오시뮬레이션 시장의 성장을 가속하는 주요 요인으로 작용하고 있습니다.

그러나 표준화된 포맷, 프로토콜, 서로 다른 시뮬레이션 플랫폼 간의 상호운용성 부족, 연구자 및 의료 전문가들의 바이오시뮬레이션 기술에 대한 인식과 교육이 제한적이라는 점이 바이오시뮬레이션 시장의 성장을 저해하는 요인으로 작용하고 있습니다. 반면, 소아 의약품 개발에서 개인 맞춤형 의료 및 바이오시뮬레이션 솔루션의 적용 확대와 사용 증가는 향후 수년간 바이오시뮬레이션 시장에 더 많은 성장 기회를 제공할 것으로 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 바이오시뮬레이션 소프트웨어의 채택 확대
    • 바이오시뮬레이션 소프트웨어의 기술적 진보
    • Drug Discovery·개발비 삭감을 위한 수요 증가
  • 억제요인
    • 표준화와 상호운용성의 결여
  • 기회
    • 바이오시뮬레이션 애플리케이션의 확대와 맞춤형 의료에 대한 수요의 증가
• COVID-19 시장에 대한 영향 분석

제4장 바이오시뮬레이션 시장 : 제품별

• 개요
• 소프트웨어
• 서비스

제5장 BIOSIMULATION 시장 : 애플리케이션별

• 개요
• 의약품 개발
• Drug Discovery
• 기타

제6장 BIOSIMULATION 시장 : 전달 모델별

• 개요
• 서브스크립션 모델
• 소유 모델

제7장 BIOSIMULATION 시장 : 최종사용자별

• 개요
• 제약기업 및 바이오테크놀러지 기업
• CRO(임상시험수탁기관)
• 학술·연구기관

제8장 BIOSIMULATION 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 호주
  • 인도
  • 한국
  • 기타
• 라틴아메리카
  • 라틴아메리카
  • 중동
  • 아프리카

제9장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제10장 기업 개요

• Certara, Inc.
• Dassault Systemes
• Simulations Plus, Inc.
• Genedata AG
• SimBioSys
• Physiomics Plc
• INOSIM Software GmbH
• VeriSIM Life
• Schrodinger, Inc.
• Cadence Design Systems, Inc.

KSA

영문 목차

영문목차

According to a new report published by Allied Market Research, titled, "Biosimulation Market," The biosimulation market was valued at $2.5 billion in 2022, and is estimated to reach $10.6 billion by 2032, growing at a CAGR of 15.8% from 2023 to 2032. The computer-assisted simulation of biological processes that are essential to human biology is known as biosimulation. The goal of biosimulation is to offer model-based predictions of the dynamics and behavior of a biological system. A simulation model translates the knowledge about the biological system into mathematical equations. In the initial stage of the drug development process, one is anticipated to use the simulation model to test any hypothesis and change the product in order to optimize its function or estimate the chances that a given agent is projected to function as a drug, even before the first molecule is produced. The simulation model is anticipated to be used as a vehicle to define an effective test protocol and to check that information obtained from tests is consistent.

Pre-clinical testing of novel medicines, lead identification and optimization, target identification and validation are some primary areas where biosimulation is being used in drug R&D. Biosimulation forms the backbone of "virtual" drug trials, whose aim is to accurately predict the way medicines and diseases behave in the body by applying principles from biology, chemistry, and pharmacology with proprietary algorithms. In addition, this work includes gathering critical insights concerning drug interactions, safe dosing, toxicity predictions, and more.

Major factors that drive the growth of the global biosimulation market include an increase in demand for drug discovery and development, rise in need for personalized medicines, and surge in technological advancement in biosimulation software and devices. For instance, in June 2022, Certara, a global leader in biosimulation, released the new versions of immunogenicity (IG), immuno-oncology (IO) and vaccine simulators to help predict how drugs work and address key questions in the development of novel biologic therapies.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, diabetes, Alzheimer's, cardiovascular disease, kidney disorders, and various others are the major factors that increase the demand for biosimulation software and hence propel the growth of the market. In addition, rise in demand to reduce drug discovery and development costs and increase in penetration of biosimulation software in contract research organization (CROs) and academic research institutes for drug discovery and development are the major factors that boost the growth of the biosimulation market.

However, the lack of standardized formats, protocols, and interoperability between different simulation platforms and limited awareness and education about biosimulation techniques among researchers and healthcare professionals restrain the growth of the biosimulation market. On the contrary, the expanding applications and increased use of personalized medicine and biosimulation solutions for pediatric drug development are expected to provide additional opportunities for the biosimulation market to grow in the coming years.

The global biosimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into software and services. On the basis of delivery model, the market is segmented into subscription model and ownership model. On the basis of application, it is segregated into drug development, drug discovery and others. On the basis of end user, it is segmented into pharmaceutical and biotechnology companies, contract research organization (CROs) and academic and research institutes. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Dassault Systemes, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PLC, INOSIM Software GmbH, Schrodinger, Inc. Simulation Plus Inc, and Cadence Design Systems, Inc. The key players such as Simulation Plus Inc, Cadence Design Systems Inc, VeriSIM Life, Certara Inc, Schrodinger Inc, and Genedata AG have adopted product launch, acquisition, collaboration, partnership, and business expansion as major developmental strategies to improve the product portfolio of the biosimulation market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimulation market analysis from 2022 to 2032 to identify the prevailing biosimulation market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the biosimulation market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global biosimulation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Product

• Software
• Services

By Application

• Drug Development
• Drug Discovery
• Others

By Delivery model

• Subscription Model
• Ownership Model

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organization (CROs)
• Academic and Research Institutes

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East
  • Africa

Key Market Players:

• SimBioSys
• Physiomics Plc
• Genedata AG
• Simulations Plus, Inc.
• Cadence Design Systems, Inc.
• Certara, Inc.
• VeriSIM Life
• Schrodinger, Inc.
• Dassault Systemes
• INOSIM Software GmbH

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Growth in adoption of biosimulation software
    • 3.4.1.2. Technological advancements in biosimulation software
    • 3.4.1.3. Increase in demand to curtail drug discovery and development costs

• 3.4.2. Restraints
  • 3.4.2.1. Lack of standardization and interoperability

• 3.4.3. Opportunities
  • 3.4.3.1. Expansion of applications of biosimulation and increase in demand for personalized medicine.

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BIOSIMULATION MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Software
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Services
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: BIOSIMULATION MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Drug Development
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Drug Discovery
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: BIOSIMULATION MARKET, BY DELIVERY MODEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Subscription Model
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Ownership Model
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: BIOSIMULATION MARKET, BY END USER

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Pharmaceutical and Biotechnology Companies
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Contract Research Organization (CROs)
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Academic and Research Institutes
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: BIOSIMULATION MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key market trends, growth factors and opportunities
  • 8.2.2. Market size and forecast, by Product
  • 8.2.3. Market size and forecast, by Application
  • 8.2.4. Market size and forecast, by Delivery model
  • 8.2.5. Market size and forecast, by End User
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Market size and forecast, by Product
    • 8.2.6.1.2. Market size and forecast, by Application
    • 8.2.6.1.3. Market size and forecast, by Delivery model
    • 8.2.6.1.4. Market size and forecast, by End User
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Market size and forecast, by Product
    • 8.2.6.2.2. Market size and forecast, by Application
    • 8.2.6.2.3. Market size and forecast, by Delivery model
    • 8.2.6.2.4. Market size and forecast, by End User
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Market size and forecast, by Product
    • 8.2.6.3.2. Market size and forecast, by Application
    • 8.2.6.3.3. Market size and forecast, by Delivery model
    • 8.2.6.3.4. Market size and forecast, by End User
• 8.3. Europe
  • 8.3.1. Key market trends, growth factors and opportunities
  • 8.3.2. Market size and forecast, by Product
  • 8.3.3. Market size and forecast, by Application
  • 8.3.4. Market size and forecast, by Delivery model
  • 8.3.5. Market size and forecast, by End User
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Market size and forecast, by Product
    • 8.3.6.1.2. Market size and forecast, by Application
    • 8.3.6.1.3. Market size and forecast, by Delivery model
    • 8.3.6.1.4. Market size and forecast, by End User
    • 8.3.6.2. France
    • 8.3.6.2.1. Market size and forecast, by Product
    • 8.3.6.2.2. Market size and forecast, by Application
    • 8.3.6.2.3. Market size and forecast, by Delivery model
    • 8.3.6.2.4. Market size and forecast, by End User
    • 8.3.6.3. UK
    • 8.3.6.3.1. Market size and forecast, by Product
    • 8.3.6.3.2. Market size and forecast, by Application
    • 8.3.6.3.3. Market size and forecast, by Delivery model
    • 8.3.6.3.4. Market size and forecast, by End User
    • 8.3.6.4. Italy
    • 8.3.6.4.1. Market size and forecast, by Product
    • 8.3.6.4.2. Market size and forecast, by Application
    • 8.3.6.4.3. Market size and forecast, by Delivery model
    • 8.3.6.4.4. Market size and forecast, by End User
    • 8.3.6.5. Spain
    • 8.3.6.5.1. Market size and forecast, by Product
    • 8.3.6.5.2. Market size and forecast, by Application
    • 8.3.6.5.3. Market size and forecast, by Delivery model
    • 8.3.6.5.4. Market size and forecast, by End User
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Market size and forecast, by Product
    • 8.3.6.6.2. Market size and forecast, by Application
    • 8.3.6.6.3. Market size and forecast, by Delivery model
    • 8.3.6.6.4. Market size and forecast, by End User
• 8.4. Asia-Pacific
  • 8.4.1. Key market trends, growth factors and opportunities
  • 8.4.2. Market size and forecast, by Product
  • 8.4.3. Market size and forecast, by Application
  • 8.4.4. Market size and forecast, by Delivery model
  • 8.4.5. Market size and forecast, by End User
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. Japan
    • 8.4.6.1.1. Market size and forecast, by Product
    • 8.4.6.1.2. Market size and forecast, by Application
    • 8.4.6.1.3. Market size and forecast, by Delivery model
    • 8.4.6.1.4. Market size and forecast, by End User
    • 8.4.6.2. China
    • 8.4.6.2.1. Market size and forecast, by Product
    • 8.4.6.2.2. Market size and forecast, by Application
    • 8.4.6.2.3. Market size and forecast, by Delivery model
    • 8.4.6.2.4. Market size and forecast, by End User
    • 8.4.6.3. Australia
    • 8.4.6.3.1. Market size and forecast, by Product
    • 8.4.6.3.2. Market size and forecast, by Application
    • 8.4.6.3.3. Market size and forecast, by Delivery model
    • 8.4.6.3.4. Market size and forecast, by End User
    • 8.4.6.4. India
    • 8.4.6.4.1. Market size and forecast, by Product
    • 8.4.6.4.2. Market size and forecast, by Application
    • 8.4.6.4.3. Market size and forecast, by Delivery model
    • 8.4.6.4.4. Market size and forecast, by End User
    • 8.4.6.5. South Korea
    • 8.4.6.5.1. Market size and forecast, by Product
    • 8.4.6.5.2. Market size and forecast, by Application
    • 8.4.6.5.3. Market size and forecast, by Delivery model
    • 8.4.6.5.4. Market size and forecast, by End User
    • 8.4.6.6. Rest of Asia-Pacific
    • 8.4.6.6.1. Market size and forecast, by Product
    • 8.4.6.6.2. Market size and forecast, by Application
    • 8.4.6.6.3. Market size and forecast, by Delivery model
    • 8.4.6.6.4. Market size and forecast, by End User
• 8.5. LAMEA
  • 8.5.1. Key market trends, growth factors and opportunities
  • 8.5.2. Market size and forecast, by Product
  • 8.5.3. Market size and forecast, by Application
  • 8.5.4. Market size and forecast, by Delivery model
  • 8.5.5. Market size and forecast, by End User
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Latin America
    • 8.5.6.1.1. Market size and forecast, by Product
    • 8.5.6.1.2. Market size and forecast, by Application
    • 8.5.6.1.3. Market size and forecast, by Delivery model
    • 8.5.6.1.4. Market size and forecast, by End User
    • 8.5.6.2. Middle East
    • 8.5.6.2.1. Market size and forecast, by Product
    • 8.5.6.2.2. Market size and forecast, by Application
    • 8.5.6.2.3. Market size and forecast, by Delivery model
    • 8.5.6.2.4. Market size and forecast, by End User
    • 8.5.6.3. Africa
    • 8.5.6.3.1. Market size and forecast, by Product
    • 8.5.6.3.2. Market size and forecast, by Application
    • 8.5.6.3.3. Market size and forecast, by Delivery model
    • 8.5.6.3.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. Certara, Inc.
  • 10.1.1. Company overview
  • 10.1.2. Key Executives
  • 10.1.3. Company snapshot
  • 10.1.4. Operating business segments
  • 10.1.5. Product portfolio
  • 10.1.6. Business performance
  • 10.1.0. Key strategic moves and developments
• 10.2. Dassault Systemes
  • 10.2.1. Company overview
  • 10.2.2. Key Executives
  • 10.2.3. Company snapshot
  • 10.2.4. Operating business segments
  • 10.2.5. Product portfolio
  • 10.2.6. Business performance
• 10.3. Simulations Plus, Inc.
  • 10.3.1. Company overview
  • 10.3.2. Key Executives
  • 10.3.3. Company snapshot
  • 10.3.4. Operating business segments
  • 10.3.5. Product portfolio
  • 10.3.6. Business performance
  • 10.3.0. Key strategic moves and developments
• 10.4. Genedata AG
  • 10.4.1. Company overview
  • 10.4.2. Key Executives
  • 10.4.3. Company snapshot
  • 10.4.4. Operating business segments
  • 10.4.5. Product portfolio
  • 10.4.0. Key strategic moves and developments
• 10.5. SimBioSys
  • 10.5.1. Company overview
  • 10.5.2. Key Executives
  • 10.5.3. Company snapshot
  • 10.5.4. Operating business segments
  • 10.5.5. Product portfolio
• 10.6. Physiomics Plc
  • 10.6.1. Company overview
  • 10.6.2. Key Executives
  • 10.6.3. Company snapshot
  • 10.6.4. Operating business segments
  • 10.6.5. Product portfolio
  • 10.6.6. Business performance
• 10.7. INOSIM Software GmbH
  • 10.7.1. Company overview
  • 10.7.2. Key Executives
  • 10.7.3. Company snapshot
  • 10.7.4. Operating business segments
  • 10.7.5. Product portfolio
• 10.8. VeriSIM Life
  • 10.8.1. Company overview
  • 10.8.2. Key Executives
  • 10.8.3. Company snapshot
  • 10.8.4. Operating business segments
  • 10.8.5. Product portfolio
  • 10.8.0. Key strategic moves and developments
• 10.9. Schrodinger, Inc.
  • 10.9.1. Company overview
  • 10.9.2. Key Executives
  • 10.9.3. Company snapshot
  • 10.9.4. Operating business segments
  • 10.9.5. Product portfolio
  • 10.9.6. Business performance
  • 10.9.0. Key strategic moves and developments
• 10.10. Cadence Design Systems, Inc.
  • 10.10.1. Company overview
  • 10.10.2. Key Executives
  • 10.10.3. Company snapshot
  • 10.10.4. Operating business segments
  • 10.10.5. Product portfolio
  • 10.10.6. Business performance
  • 10.10.0. Key strategic moves and developments

관련자료